Cardiff Oncology Inc (CRDF) Quote

CRDF...................................................https://stockcharts.com/h-sc/ui?s=CRDF&p=W&b=5&g=0&id=p86431144783

CRDF new 52 hi

CRDF.........................https://stockcharts.com/h-sc/ui?s=CRDF&p=W&b=5&g=0&id=p86431144783

CRDF................................https://stockcharts.com/h-sc/ui?s=CRDF&p=W&b=5&g=0&id=p86431144783

CRDF new 52 week hi

PIper Sandler raises price target on CRDF from $5 to $7. Stock up 25%.

Bladerunner

CRDF: Change of opinion by "Seeking Alpha" analyst

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar. 08, 2024 7:37 PM ET Cardiff Oncology, Inc. (CRDF) Stock 8 Comments2 Likes




Galzus Research

Summary
Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients.
The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy.
Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.


Topline Summary and UpdateCardiff Oncology (NASDAQ: CRDF) is a cancer-focused biotech working on developing a drug that exploits a novel target, particularly in colorectal cancer. In my past articles, I have been lukewarm to slightly pessimistic about their findings presented to date and their overall outlook. But recent news has sent them on a meteoric rise, and the ensuing roller coaster has readers asking me directly for input on this company. So let's examine what happened to lead to this strong rise in value, as well as where I think they might be headed next.

Pipeline UpdatesOnvansertib

Today, the PLK1 inhibitor onvansertib remains the one and only drug in development by CRDF, meaning its entire future rests on the success or failure of this agent. It is being studied mainly in a few forms of gastrointestinal cancer, namely colorectal cancer and pancreatic cancer, both representing critical unmet needs in oncology.

Most of the focus I've given in my previous writings has been for the colorectal cancer program, which has demonstrated some encouraging (though early) activity in the setting of KRAS -mutant, metastatic disease. Updated findings using add-on onvansertib with FOLFIRI-bevacizumab in the second-line setting have since been published in Clinical Cancer Research, showing a 44% response rate among 18 patients, with reasonable toxicity.

Now, the company's focus is on moving onvansertib to the first-line setting, hurdling over the typical path we have taken in targeted therapy development of starting with more "dire" clinical settings, establishing efficacy, and then moving them up. The phase 2 CRDF-004 study is seeking to randomize 90 patients with newly diagnosed, metastatic, KRAS or NRAS mutated CRC to receive first-line doublet chemotherapy plus bevacizumab, with or without one of 2 doses of onvansertib. The primary endpoint is objective response rate. CRDF announced that the first patient was dosed in this study on leap day. Initial top-line findings are anticipated later this year.

The phase 2 ONSEMBLE second-line study has been discontinued to focus on the frontline study, but CRDF provided an update in their most recent guidance that they interpret as evidence that patients who had no prior bevacizumab seemed to have better response rates, as high as 50%. It is worth keeping in mind that the patient numbers are small here, and in the standard of care, most patients with KRAS mutated mCRC are going to receive bevacizumab as part of their care, so it's difficult to interpret these findings with any real de

We've also gotten glimpses of clinical development for onvansertib in non-CRC settings. Most notably, a report of activity back in September suggests preliminary benefit from onvansertib in metastatic pancreatic cancer and extensive-stage small cell lung cancer. In particular, 4 of 21 patients with pancreatic cancer treated with add-on onvansertib (plus nal-IRI and 5-FU) yielding a 19% objective response rate, which tracks favorably with the findings from NAPOLI-1. A single response was observed with onvansertib monotherapy in the 7 patients with SCLC.

Financial OverviewAs of their most recent earnings report, CRDF held $77.4 million in total current assets, including $21.7 million in cash and equivalents, and another $53.2 million in short-term investments. Their reported annual loss was $45.4 million, with a recognized net loss of $41.4 million after interest income and other expenses.

Given these expenses, CRDF has upwards of 2 years of cash and assets on hand to fund activities, with a serious going concern emerging about a year from now at the current burn rate, by my estimation. This is consistent with guidance from the company saying they have funds to operate through Q3 2025.

Strengths and RisksStrength - CRDF's fiscal management focuses on high-priority studies

For a company in the middle of developing a drug, CRDF has a rather low cash burn rate. This could help give them time to get a data readout that propels them to the levels that we've seen recently with the likes of Janux Therapeutics, where relatively small numbers rev up a huge cash raise. Such penny-pinching stewardship is admirable, although there is a catch

Risk - Careful prioritization places most eggs in one basket

CRDF is now resting almost everything on the CRDF-004 study, and this trial is taking a risky step moving things into the frontline setting. Despite it being at the FDA's recommendation (according to the company), the observation in their 2 early studies that bevacizumab-naive patients seemed to derive the most benefit from onvansertib is shaky to me. These are small patient numbers, and I don't feel this is a hypothesis that's been carried through rigorously enough at this point.

That doesn't mean I think they're wrong, and I don't think it's a wantonly reckless step to go first line. If onvansertib really does work best in bev-naive patients, then this should end up being the exact play they need to make. But it's based on an idea that comes from pretty small patient numbers, and CRDF-004 may not generate convincing-enough findings to really show that onvansertib is moving the needle. All investors should be aware of that risk before jumping in.

Bottom-Line Summary: Why the Rating Change?As of late, developmental biotech companies are undergoing a surge of interest, with multiple companies showing promising phase 1 data sending them into market caps of billions. I do not think this is necessarily justified, but it speaks to the power of encouraging early data. CRDF, even after its recent gains, has the opportunity to surge even higher if their anticipated mid-2024 data readout in CRC shows support for their idea that onvansertib has more benefit in patients with no exposure to bevacizumab (which would be true of all first-line patients).

Tackling KRAS would be a huge coup, since there are currently no approved therapies that are specifically beneficial for patients in the frontline setting of mCRC with KRAS mutations. It's only used right now to help determine what therapies patients should not receive.

All said, I'm upgrading my rating to a "strong buy," which means that I think you should take a serious look at their portfolio and consider entering into a limited position. I would warn heavily against overextending, though, since so much of the company's value is now going to be tied to the outcomes of a single trial, and a lot can go wrong there. But it is clear now that the ceiling is too high to ignore for this company.

Bladerunner

CRDF.........................................https://stockcharts.com/h-sc/ui?s=CRDF&p=W&b=5&g=0&id=p86431144783

4s then 5 coming

Is this company being taken out? Incredible volume.

That post wasn’t too long ago
What I did several weeks ago was access the Barchart.com website which has lists of stocks belonging to sectors
I clicked for the biomedical sector up and .came up with a list and I wrote down every stock priced under $2USD and stated posting about each one
The list was for over 100 stocks
Get over $2 and the stock has a chance for higher prices

CRDF..........................................https://stockcharts.com/h-sc/ui?s=CRDF&p=W&b=5&g=0&id=p86431144783

Here comes 3

CRDF over $2 heading for $3

GhosT

CRDF under $2

CRDF under $2

CRDF under $2

Looking like a good set it and forget it to stock. Pfizer thinks so too.

https://finance.yahoo.com/news/cardiff-oncology-announces-positive-clinical-200500411.html

https://www.otcmarkets.com/filing/html?id=16949869&guid=Vag-kao64zK-B3h#a992ex09262023_htm
ardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Baird apparently think it is worthwhile to remain invested in CRDF

So did people not think the data was good? It tanked after data release

Lets GO $CRDF!!

GL

Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative

https://www.prnewswire.com/news-releases/cardiff-oncology-announces-15-million-equity-investment-from-pfizer-through-its-pfizer-breakthrough-growth-initiative-301427783.html

Isn't the primary completion expected Oct 31?

Shares of Cardiff Oncology Inc. are trading higher. The company released new data on its lead clinical program evaluating onvansertib to treat certain colorectal cancer patients.

Cardiff Oncology said the program is evaluating onvansertib in combination with standard-of-care Folfiri/bevacizumab to treat certain colorectal cancer patients.

"Our Phase 1b/2 trial continues to generate data suggesting that the addition of onvansertib to SOC results in an objective response rate and median progression-free survival that substantially exceed those previously achieved with SOC alone," said Katherine L. Ruffner, chief medical officer.

Filing Form 4 > CFO > 90k shares, > direct Buy.

SEC Filing FORM 4

CRDF

30,000 shares insider direct buy. Something going on.

$CRDF: $25 Piper Sandler PRICE Target


Now at $7







GO $CRDF

$CRDF: After HOURS popper now..... 8.24


Look at her rip now



GO $CRDF

Doesn’t look like there is any technical support for this until $5 range. With no scheduled trial news until September looks like we could test support?

GLTA,

Murocman

Analysts Say ‘Buy the Pullback
Cardiff Oncology (CRDF)

The first stock we’re looking at, Cardiff Oncology, is a clinical stage biopharma company with a laser-focus on cancer treatment. Specifically, the company focuses on the development of medication options for cancer patients whose current treatment has lost efficacy. Cardiff is developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, designed to work in combination with existing medications to overcome treatment resistance, improve patient response, and increase survival rates.
Cardiff’s current research pipeline features onvansertib in three separate clinical programs, in combination with different existing drugs to combat three different cancers. The programs are a Phase 1b clinical trial of onvansertib plus Folfiri/Avastin for the treatment of KRAS-Mutated Metastatic Colorectal Cancer (mCRC), and two Phase 2 trials, one in combination with Zytiga to treat Metastatic Castration-Resistant Prostate Cancer (mCRPC) and one to treat Relapsed/Refractory Acute Myeloid Leukemia (AML) in combination with Decitabine.

Preliminary data on these studies shows positive responses to onvansertib in combination with existing therapies. In the mCRC program, 86% of evaluable patients have shown a clinical benefit, while in the mCRPC program 54% of patients across three cohorts showed a radiographic stable disease. In the AML program, 20% of patients achieved a complete remission. These early data are considered significant, and the company has plans to initiate further trials later this year.

This background, along with the stock’s 50% fall year-to-date, have combined to catch the attention of 5-star analyst Jason McCarthy of Maxim Group. McCarthy points out that the shares have retreated recently due to profit-taking and broader market changes.

“While valuation has pulled back since reaching a 52-week high in late 4Q, from a KRAS perspective, CRDF is not alone… and we view Cardiff as potentially having the more attractive asset in mCRC which continues to be supported with emerging data… we still see a KRAS space that will continue to be active and is of potential high value given the unmet need, a company in Cardiff that is well-financed ($130M in cash as of YE20), and a drug in onvansertib that has multiple opportunities. Combined, we see this as an opportunity to buy CRDF shares on the weakness,” McCarthy opined. McCarthy puts a Buy rating on CRDF, and his $30 price target implies a robust upside of 242% from current levels.

https://www.tipranks.com/news/article/analysts-say-buy-the-pullback-in-these-3-stocks-2/

at that time CRDF had dropped on good news, and I bot options, but the pps was so slow moving I finally bailed and didn't look back...

Why do you think that? Still sitting on 18,600 shares. I should have sold at $30

Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase in Efficacy with an Optimized Onvansertib Dosing Schedule

https://www.prnewswire.com/news-releases/cardiff-oncology-presents-phase-2-mcrpc-trial-data-showing-a-two-fold-increase-in-efficacy-with-an-optimized-onvansertib-dosing-schedule-301226711.html

CRDF on its way up...

Was good dip Friday

tanx, U 2!!! CRDF has some wild swings!!! would like to see it go back into 20's in next 2 weeks...

Nice! Best of luck.

checked on CRDF today...NICE bounce!!! I bot me some options, hopefully we see this continue on with FDA clearance of more testing...

I bot 25 options CRDF Feb 19 '21 $15 Call @ .90 ...pps was close to 11.17 my order filled on the dip...

explains the recovery mode on the chart...CRDF had positive results...

$CRDF is headed for the top after announcing that it has receive permission to move forward with a Phase 2 trial from the FDA. https://cnafinance.com/crdf-stock-cardiff-oncology-to-proceed-with-phase-2-study/

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

https://finance.yahoo.com/news/cardiff-oncology-receives-study-may-130000213.html

Yeah, I don't get it. Markets are red today. Results look good, mind-boggling.

panic selling for good results??? CRDF looks like good time to buy...

Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

https://www.prnewswire.com/news-releases/cardiff-oncology-presents-data-that-continues-to-demonstrate-the-clinical-benefit-of-onvansertib-in-kras-mutated-mcrc-and-initial-findings-from-its-expanded-access-program-301209151.html

Cardiff Oncology initiated with a Buy at H.C. Wainwright

Cardiff Oncology initiated with a Buy at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Cardiff Oncology with a Buy rating and $27 price target. The company's lead clinical-stage candidate, onvansertib, is a potent, highly selective, third-generation inhibitor of Polo-like kinase 1, Selvaraju tells investors in a research note. The analyst believes onvansertib could constitute a "best-in-class" Plk1 inhibitor.

https://thefly.com/n.php?id=3179540

Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance

https://www.prnewswire.com/news-releases/cardiff-oncology-presents-positive-efficacy-and-biomarker-data-from-mcrpc-trial-demonstrating-ability-of-onvansertib-to-overcome-zytiga-resistance-301155618.html

Good luck T t